Published on November 20, 2009 at 4:39 AM
Research and Markets (http://www.researchandmarkets.com/research/fae4d4/neurological_disea) has announced the addition of Decision Resources, Inc.'s new report "Neurological Disease: Early-Stage R&D and Dealmaking" to their offering.
How can early-stage R&D efforts be positioned to tap the remaining opportunity in the neurology drug market? Although brimming with potential, neurology drug development is also rife with unique challenges that many companies and agents have been unable to overcome, as witnessed by the failures of agents initially deemed highly promising. However, careful planning—including risk mitigation through strategic collaboration—can allow a drug developer to take advantage of the significant opportunity in this market.
Questions Answered in This Report
Although therapies are available for neurological disorders, most of these conditions remain under treated, and no cures are available.
- What benefits do novel therapies have over existing treatment options?
- How can companies mitigate the risk associated with drug development?
Much of the innovation in drug discovery and design occurs in small companies.
- What companies are developing novel approaches to treat neurological diseases?
- What collaborations have they forged with Big Pharma?
The neurology market is entering a period of stagnation.
- What is currently driving market growth?
- What are the greatest needs in the treatment of neurological diseases?
Scope
- Novel targets for neurology: Beta-amyloid, beta-secretase, tau protein, NMDA, nicotinic acetylcholinesterase receptor, HMG-CoA reductase.
- Novel technologies for neurology: Deep-brain stimulation, stem cell therapy.
- Focus on diseases with neuronal degradation as a primary symptom: Alzheimer's disease (AD), mild cognitive impairment (MCI), multiple sclerosis (MS), Parkinson's disease (PD), Huntington's disease (HD), ALS and other motor neuron diseases.
Company profiles: Lundbeck, CoMentis, Targacept, Vitae Pharmaceuticals.
- Outlook: Challenges in drug development, recent deal making, need for increased research, benefits of academic collaborations.
http://www.researchandmarkets.com/research/fae4d4/neurological_disea
72f65c0f-1333-481c-ae59-78ccabc0d372|0|.0
Posted in: Medical Condition News | Pharmaceutical News
Tags: Alzheimer's Disease, Brain, Cell, Huntington's Disease, Neurological Disease, Neurology, Neuron, Parkinson's Disease, Protein, Stem Cell, Tau Protein